Emphysema Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034)

The emphysema treatment market was valued at USD 4.65 billion in 2024, driven by the rising incidence of chronic lung conditions and the growing focus on respiratory health across the 8 major markets. The market is anticipated to grow at a CAGR of 5.7% during the forecast period 2025-2034 to reach a value of USD 7.66 billion by 2034.

Emphysema Treatment Market Outlook

  • The increasing cases of emphysema, driven by factors like smoking, environmental pollutants, and the growing aging population, is a primary driver of the market.
  • The rising emphasis on respiratory health and government support for early diagnosis and management of chronic respiratory diseases is anticipated to elevate the market value during the forecast period.
  • The expanding research into regenerative medicine and stem cell therapies is a significant market trend that is attracting substantial investment from both the public and private sectors.
Emphysema Treatment Market Overview

Emphysema (a type of chronic obstructive pulmonary disease (COPD)) is a lung condition that leads to shortness of breath due to the damage caused to the air sacs (alveoli) in the lungs. The increase in the number of tobacco smokers is driving the growth of the market. The growing prevalence of chronic lung disorders and the availability of advanced diagnostic facilities are resulting in the increased demand for emphysema treatments. Moreover, factors such as increasing sedentary lifestyles, growing urbanization and industrialization, and rising pollution levels are further propelling market expansion. Additionally, the growing research and development activities and the advancements in the medical sector are expected to impact the market dynamics positively.

Emphysema Treatment Market Growth Drivers

Increasing Prevalence of Emphysema Drives Market Growth

In the United States, around 14 million  people are affected by emphysema, which includes 14% white male smokers and 3% white male nonsmokers. The prevalence is reported slightly lower in white female smokers and African Americans. The severity of the emphysema is substantially higher in coal worker pneumoconiosis, irrespective of smoking status. The rising incidence of emphysema, as a result of an increase in cigarette smoking and environmental pollution, is expected to fuel the market growth.

Emphysema Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rising Launch of Generic Medications to Affect the Market Landscape Significantly

The increasing availability of generic treatments is projected to impact the market growth. For instance, in July 2023 , Viatris Inc. (an American global pharmaceutical company) and Kindeva Drug Delivery L.P. (a pharmaceutical contract development and manufacturing organization (CDMO)) announced the launch of its drug-device combination product Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, which is the first generic version of AstraZeneca’s Symbicort. Breyna is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD), including emphysema and/or chronic bronchitis.

Increased Adoption of Combination Therapies Poised to Augment Emphysema Treatment Market Demand

One of the major market trends is the rising preference for combination therapies, such as long-acting bronchodilators paired with inhaled corticosteroids. These combination treatments not only help in managing the symptoms more effectively but can also slow the progression of emphysema and the frequency of exacerbations, thereby improving the patient’s quality of life. The rising integration of combination therapies into treatment protocols is likely to augment the market demand.

Increased Research to Elevate the Emphysema Treatment Market Value

In January 2024 , a study published in JCI Insight revealed that a novel KF4 antibody that works by blocking chymotrypsin-like elastase 1 (CELA1) can significantly reduce lung damage as a result of diseases such as chronic obstructive pulmonary disease (COPD) and age-related emphysema in mice. Such research activities that show potential in slowing emphysema progression are set to elevate the market value in the coming years.

Advancements in Treatment Options to Boost Emphysema Treatment Market Size

The rising advancements in treatment options are poised to shape the market landscape positively. Lung volume reduction surgeries (LVRS) and procedures like endobronchial valve placement are rising in popularity as they are less invasive in nature compared to traditional methods for the treatment of severe emphysema. In addition, the emergence of biologic therapies targeting specific inflammatory pathways is anticipated to boost the market size in the forecast period.

Emphysema Treatment Market Segmentation

Market Breakup by Type
  • Centriacinar
  • Panacinar
  • Paraseptal
  • Others
Market Breakup by Treatment Type
  • Medication
  • Bronchodilators
  • Steroids
  • Others
  • Surgery
  • Others
Market Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Market Breakup by End User
  • Hospitals
  • Homecare Settings
  • Specialty Clinics
  • Others
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom 
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India
Emphysema Treatment Market Share

The Type Segment is Anticipated to Witness Substantial Growth

Based on the type, the market is segmented into centriacinar, panacinar, and paraseptal, among others. Centriacinar dominates the market share as it is the most common type of emphysema, starting in the respiratory bronchioles and affecting the upper half of the lungs. This emphysema type is usually associated with long-term cigarette smoking. On the other hand, panacinar emphysema is caused by a rare genetic disease called homozygous alpha-1 antitrypsin deficiency. It typically occurs in the lower half of the lungs.

Emphysema Treatment Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is one of the major markets for emphysema treatment owing to the high prevalence of chronic obstructive pulmonary disease (COPD) and increasing environmental pollution in the region. The availability of advanced treatments such as minimally invasive procedures and biologic therapies also benefits the market growth. Moreover, the presence of a robust regulatory framework and increasing focus on respiratory health is poised to aid market expansion in the country.

Leading Players in the Emphysema Treatment Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Pfizer Inc.

American multinational pharmaceutical industry company Pfizer is one of the leading players in the market. SPIRIVA HandiHaler  (tiotropium bromide inhalation powder) is a prescription medication developed by Pfizer that helps in the management of symptoms of chronic obstructive pulmonary disease (COPD) including emphysema.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd., headquartered in Basel, Switzerland, has a prominent presence in the market. The company is engaged in introducing new treatments for emphysema by investing in the clinical development of potential medications such as the monoclonal antibody astegolimab.

Mylan N.V.

Mylan N.V., a global healthcare company developing generic and specialty pharmaceuticals, merged with Pfizer's off-patent medicine division (Upjohn) to form Viatris. The company is focused on advancing respiratory care by leveraging strategic partnerships and collaborations with other market players.

Fresenius Kabi AG

Headquartered in Bad Homburg, Germany, Fresenius Kabi AG is a key market player that manufactures and commercializes infusion therapy and clinical nutrition products.

Other key players in the market include Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK Plc, Bayer AG, Intersect ENT, Inc., and Sun Pharmaceutical Industries Ltd.

Key Questions Answered in the Emphysema Treatment Market Report
  • What was the emphysema treatment market value in 2023?
  • What is the emphysema treatment market forecast outlook for 2025-2034?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on type?
  • What is the market breakup based on treatment type?
  • What is the market breakup by treatment channel?
  • What are the major distribution channels in the market?
  • What are the major factors aiding the emphysema treatment market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints?
  • Which regional market is expected to lead the market share in the forecast period?
  • Which country is expected to experience expedited growth during the forecast period?
  • How do the prevalence and incidence of emphysema affect the market landscape?
  • What are the major emphysema treatment market trends?
  • How does the rise in the geriatric population impact the market size?
  • Which type will dominate the market share?
  • Which treatment type is expected to have a high market value in the coming years?
  • Which treatment channel will experience the highest demand in the market segment?
  • Which distribution channel is projected to contribute to the highest market growth?
  • Who are the key players involved in the emphysema treatment market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Emphysema Treatment Market Overview: 8 Major Market
3.1 Emphysema Treatment Market Historical Value (2018-2024)
3.2 Emphysema Treatment Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Emphysema Treatment: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Emphysema Treatment Market Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Emphysema Treatment Market Landscape: 8 Major Market*
8.1 Emphysema Treatment Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Emphysema Treatment Market: Product Landscape
8.2.1 Analysis by Type
8.2.2 Analysis by Treatment Type
8.2.3 Analysis by Route of Administration
9 Emphysema Treatment Market Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Emphysema Treatment Market: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Emphysema Treatment Market Segmentation: 8 Major Markets
12.1 Emphysema Treatment Market (2018-2034) by Type
12.1.1 Market Overview
12.1.2 Centriacinar
12.1.3 Panacinar
12.1.4 Paraseptal
12.1.5 Others
12.2 Emphysema Treatment Market (2018-2034) by Treatment Type
12.2.1 Market Overview
12.2.2 Medication
12.2.2.1 Bronchodilators
12.2.2.2 Steroids
12.2.2.3 Others
12.2.3 Surgery
12.2.4 Others
12.3 Emphysema Treatment Market (2018-2034) by Route of Administration
12.3.1 Market Overview
12.3.2 Oral
12.3.3 Parenteral
12.3.4 Others
12.4 Emphysema Treatment Market (2018-2034) by End User
12.4.1 Market Overview
12.4.2 Hospitals
12.4.3 Homecare Settings
12.4.4 Specialty Clinics
12.4.5 Others
12.5 Emphysema Treatment Market (2018-2034) by Distribution Channel
12.5.1 Market Overview
12.5.2 Hospital Pharmacy
12.5.3 Retail Pharmacy
12.5.4 Online Pharmacy
12.5.5 Others
12.6 Emphysema Treatment Market (2018-2034) by Region
12.6.1 Market Overview
12.6.2 United States
12.6.3 EU-4 and the United Kingdom
12.6.3.1 Germany
12.6.3.2 France
12.6.3.3 Italy
12.6.3.4 Spain
12.6.3.5 United Kingdom
12.6.4 Japan
12.6.5 India
13 United States Emphysema Treatment Market (218-2034)
13.1 United States Emphysema Treatment Market Historical Value (2018-2024)
13.2 United States Emphysema Treatment Market Forecast Value (2025-2034)
13.3 United States Emphysema Treatment Market (2018-2034) by Type
13.3.1 Market Overview
13.3.2 Centriacinar
13.3.3 Panacinar
13.3.4 Paraseptal
13.3.5 Others
13.4 United States Emphysema Treatment Market (2018-2034) by Treatment Type
13.4.1 Market Overview
13.4.2 Medication
13.4.2.1 Bronchodilators
13.4.2.2 Steroids
13.4.2.3 Others
13.4.3 Surgery
13.4.4 Others
13.5 United States Emphysema Treatment Market (2018-2034) by Route of Administration
13.5.1 Market Overview
13.5.2 Oral
13.5.3 Parenteral
13.5.4 Others
13.6 United States Emphysema Treatment Market (2018-2034) by End User
13.6.1 Market Overview
13.6.2 Hospitals
13.6.3 Homecare Settings
13.6.4 Specialty Clinics
13.6.5 Others
13.7 United States Emphysema Treatment Market (2018-2034) by Distribution Channel
13.7.1 Market Overview
13.7.2 Hospital Pharmacy
13.7.3 Retail Pharmacy
13.7.4 Online Pharmacy
13.7.5 Others
14 EU-4 and United Kingdom Emphysema Treatment Market (218-2034)
14.1 EU-4 and United Kingdom Emphysema Treatment Market Historical Value (2018-2024)
14.2 EU-4 and United Kingdom Emphysema Treatment Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by Type
14.3.1 Market Overview
14.3.2 Centriacinar
14.3.3 Panacinar
14.3.4 Paraseptal
14.3.5 Others
14.4 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by Treatment Type
14.4.1 Market Overview
14.4.2 Medication
14.4.2.1 Bronchodilators
14.4.2.2 Steroids
14.4.2.3 Others
14.4.3 Surgery
14.4.4 Others
14.5 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by Route of Administration
14.5.1 Market Overview
14.5.2 Oral
14.5.3 Parenteral
14.5.4 Others
14.6 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by End User
14.6.1 Market Overview
14.6.2 Hospitals
14.6.3 Homecare Settings
14.6.4 Specialty Clinics
14.6.5 Others
14.7 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by Distribution Channel
14.7.1 Market Overview
14.7.2 Hospital Pharmacy
14.7.3 Retail Pharmacy
14.7.4 Online Pharmacy
14.7.5 Others
15 Japan Emphysema Treatment Market
15.1 Japan Emphysema Treatment Market Historical Value (2018-2024)
15.2 Japan Emphysema Treatment Market Forecast Value (2025-2034)
15.3 Japan Emphysema Treatment Market (2018-2034) by Type
15.3.1 Market Overview
15.3.2 Centriacinar
15.3.3 Panacinar
15.3.4 Paraseptal
15.3.5 Others
15.4 Japan Emphysema Treatment Market (2018-2034) by Treatment Type
15.4.1 Market Overview
15.4.2 Medication
15.4.2.1 Bronchodilators
15.4.2.2 Steroids
15.4.2.3 Others
15.4.3 Surgery
15.4.4 Others
15.5 Japan Emphysema Treatment Market (2018-2034) by Route of Administration
15.5.1 Market Overview
15.5.2 Oral
15.5.3 Parenteral
15.5.4 Others
15.6 Japan Emphysema Treatment Market (2018-2034) by End User
15.6.1 Market Overview
15.6.2 Hospitals
15.6.3 Homecare Settings
15.6.4 Specialty Clinics
15.6.5 Others
15.7 Japan Emphysema Treatment Market (2018-2034) by Distribution Channel
15.7.1 Market Overview
15.7.2 Hospital Pharmacy
15.7.3 Retail Pharmacy
15.7.4 Online Pharmacy
15.7.5 Others
16 India Emphysema Treatment Market
16.1 India Emphysema Treatment Market Historical Value (2018-2024)
16.2 India Emphysema Treatment Market Forecast Value (2025-2034)
16.3 India Emphysema Treatment Market (2018-2034) by Type
16.3.1 Market Overview
16.3.2 Centriacinar
16.3.3 Panacinar
16.3.4 Paraseptal
16.3.5 Others
16.4 India Emphysema Treatment Market (2018-2034) by Treatment Type
16.4.1 Market Overview
16.4.2 Medication
16.4.2.1 Bronchodilators
16.4.2.2 Steroids
16.4.2.3 Others
16.4.3 Surgery
16.4.4 Others
16.5 India Emphysema Treatment Market (2018-2034) by Route of Administration
16.5.1 Market Overview
16.5.2 Oral
16.5.3 Parenteral
16.5.4 Others
16.6 India Emphysema Treatment Market (2018-2034) by End User
16.6.1 Market Overview
16.6.2 Hospitals
16.6.3 Homecare Settings
16.6.4 Specialty Clinics
16.6.5 Others
16.7 India Emphysema Treatment Market (2018-2034) by Distribution Channel
16.7.1 Market Overview
16.7.2 Hospital Pharmacy
16.7.3 Retail Pharmacy
16.7.4 Online Pharmacy
16.7.5 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Pfizer Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Company News and Developments
23.2.5 Certifications
23.3 F. Hoffmann-La Roche Ltd.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Company News and Developments
23.3.5 Certifications
23.4 Mylan N.V.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Company News and Developments
23.4.5 Certifications
23.5 Fresenius Kabi AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Company News and Developments
23.5.5 Certifications
23.6 Hikma Pharmaceuticals PLC
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Company News and Developments
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Company News and Developments
23.7.5 Certifications
23.8 Teva Pharmaceutical Industries Ltd.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Company News and Developments
23.8.5 Certifications
23.9 Bristol Myers Squibb Company
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Company News and Developments
23.9.5 Certifications
23.10 GSK Plc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Company News and Developments
23.10.5 Certifications
23.11 Bayer AG
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Company News and Developments
23.11.5 Certifications
23.12 Sun Pharmaceutical Industries Ltd.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Company News and Developments
23.12.5 Certifications
23.13 Intersect ENT, Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Company News and Developments
23.13.5 Certifications
24 Emphysema Treatment Market – Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings